Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359987 | 0.74 | CA1 (0.39) | POLB | |
| SCHEMBL8165313 | 0.74 | CA1 (0.39) | POLB | |
| SCHEMBL1381228 | 0.74 | KDM4E (0.32) | POLB | |
| SCHEMBL107630 | 0.74 | CA1 (0.39) | POLB | |
| SCHEMBL1381231 | 0.73 | CYP19A1 (0.36) | POLB | |
| SCHEMBL3538561 | 0.73 | CYP19A1 (0.32) | POLB | |
| SCHEMBL8678117 | 0.73 | MEN1 (0.33) | POLB | |
| SCHEMBL1182269 | 0.71 | CYP19A1 (0.31) | — | |
| SCHEMBL7916781 | 0.70 | — | — | |
| SCHEMBL8053904 | 0.70 | CYP19A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4717006-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | claimed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | claimed |
| EP-1687292-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005051940-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7897789-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | LU JIANLIANG | 2010-03-25 | — | — | US | disclosed |
| US-7659296-B2 | 2-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid; 1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid amide; stimulate bone formation, restore bone quality, acne, alopecia, Alzheimer's disease etc. | ELI LILLY AND COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-7582775-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1687292-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006069153-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006069154-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005051940-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | POLB 4766/4885 |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | POLB 4591/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | POLB 4532/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | POLB 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.